Stifel analyst Paul Matteis reiterated a Buy rating and $60.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments